Davidson Kempner Capital Management’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Davidson Kempner Capital Management’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-50,000	Closed	-$498K	–	637
2021 Q3	$498K	Hold	50,000	–	–	0.01%	342
2021 Q2	$498K	Hold	50,000	–	–	﹤0.01%	418
2021 Q1	$498K	Buy	+50,000	New	+$517K	0.01%	383

Other funds holding PRDS

FCMV

Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

FCOMV

Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

JCM

JS Capital Management New York $109M AUM 34.13% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Davidson Kempner Capital Management's PRDS Position: Q4 2021 in Review

Davidson Kempner Capital Management sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q4 2021, closing a stake of 50,000 shares — an estimated $498K sold.

Davidson Kempner Capital Management first reported a position in PRDS in Q1 2021 and held it in 3 quarters. The position peaked at $498K in Q3 2021. 41 funds tracked by Wall St. Rank hold PRDS as of Q4 2021.

Davidson Kempner Capital Management reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Davidson Kempner Capital Management sold 50,000 Pardes Biosciences, Inc. Common Stock shares in Q4 2021, an estimated $498K.
Davidson Kempner Capital Management first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
Davidson Kempner Capital Management's Pardes Biosciences, Inc. Common Stock position peaked at $498K in Q3 2021.
41 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q4 2021.

Based on Davidson Kempner Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.